CN107922356A - [4‑(1,3,3‑三甲基‑2‑氧代‑3,4‑二氢‑1h‑喹喔啉‑7‑基)苯氧基]乙基氧基化合物或其盐 - Google Patents

[4‑(1,3,3‑三甲基‑2‑氧代‑3,4‑二氢‑1h‑喹喔啉‑7‑基)苯氧基]乙基氧基化合物或其盐 Download PDF

Info

Publication number
CN107922356A
CN107922356A CN201680049254.XA CN201680049254A CN107922356A CN 107922356 A CN107922356 A CN 107922356A CN 201680049254 A CN201680049254 A CN 201680049254A CN 107922356 A CN107922356 A CN 107922356A
Authority
CN
China
Prior art keywords
disease
group
compound
dihydro
trimethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680049254.XA
Other languages
English (en)
Chinese (zh)
Inventor
川岛健二
山崎裕辅
高冈慎治
椎大介
小田知子
松山高央
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Santen Pharmaceutical Co Ltd
Original Assignee
Santen Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santen Pharmaceutical Co Ltd filed Critical Santen Pharmaceutical Co Ltd
Publication of CN107922356A publication Critical patent/CN107922356A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509—Six-membered rings
    • C07F9/650952—Six-membered rings having the nitrogen atoms in the positions 1 and 4
    • C07F9/650994—Six-membered rings having the nitrogen atoms in the positions 1 and 4 condensed with carbocyclic rings or carbocyclic ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201680049254.XA 2015-08-25 2016-08-25 [4‑(1,3,3‑三甲基‑2‑氧代‑3,4‑二氢‑1h‑喹喔啉‑7‑基)苯氧基]乙基氧基化合物或其盐 Pending CN107922356A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2015166247 2015-08-25
JP2015-166247 2015-08-25
PCT/JP2016/074863 WO2017034006A1 (ja) 2015-08-25 2016-08-25 ［４－（１，３，３－トリメチル－２－オキソ－３，４－ジヒドロ－１ｈ－キノキサリン－７－イル）フェノキシ］エチルオキシ化合物またはその塩

Publications (1)

Publication Number Publication Date
CN107922356A true CN107922356A (zh) 2018-04-17

Family

ID=58100493

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680049254.XA Pending CN107922356A (zh) 2015-08-25 2016-08-25 [4‑(1,3,3‑三甲基‑2‑氧代‑3,4‑二氢‑1h‑喹喔啉‑7‑基)苯氧基]乙基氧基化合物或其盐

Country Status (9)

Country Link
US (3) US10189796B2 (https=)
EP (1) EP3342768A4 (https=)
JP (2) JP2017043614A (https=)
KR (1) KR20180043329A (https=)
CN (1) CN107922356A (https=)
CA (1) CA2996278A1 (https=)
EA (1) EA201890570A1 (https=)
HK (1) HK1252159A1 (https=)
WO (1) WO2017034006A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107922356A (zh) * 2015-08-25 2018-04-17 参天制药株式会社 [4‑(1,3,3‑三甲基‑2‑氧代‑3,4‑二氢‑1h‑喹喔啉‑7‑基)苯氧基]乙基氧基化合物或其盐
US20200121652A1 (en) 2017-06-16 2020-04-23 The Doshisha Compounds having caspase inhibitory activity, pharmaceutical agent containing said compounds and for treating or preventing corneal endothelial symptoms, disorders, or diseases, and application of said pharmaceutical agent
EP3639854B1 (en) 2017-06-16 2026-01-07 The Doshisha Mtor-inhibitor-containing medicine for treating or preventing fuchs' endothelial corneal dystrophy
AR113967A1 (es) 2017-12-18 2020-07-01 Gruenenthal Gmbh Pirrolidinamidas i sustituidas
TW201927769A (zh) 2017-12-18 2019-07-16 德商歌林達有限公司 經取代之吡咯啶醯胺ｉｉ
IL280212B2 (en) * 2018-07-20 2023-09-01 Gruenenthal Chemie Transmuted triazoloquinoxaline histories
TWI811400B (zh) 2018-07-20 2023-08-11 德商歌林達有限公司 經進一步取代之三唑并喹噁啉衍生物
JP7446316B2 (ja) 2019-01-11 2024-03-08 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 置換ピロリジンアミドｉｉｉ
EP3986885B1 (en) 2019-06-19 2023-05-03 Grünenthal GmbH Substituted pyrrolidine amides iv
EP3986886A2 (en) 2019-06-19 2022-04-27 Grünenthal GmbH Substituted pyrrolidine amides v
ES3025970T3 (en) * 2020-01-17 2025-06-10 Gruenenthal Gmbh Quinoxaline derivatives as modulators of the glucocorticoid receptor
WO2021144439A1 (en) * 2020-01-17 2021-07-22 Grünenthal GmbH Quinoxaline derivatives
WO2022008705A1 (en) 2020-07-09 2022-01-13 Grünenthal GmbH Substituted pyrrolidine amines and amides as mediator of the glucocortoid receptor

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009035068A1 (ja) * 2007-09-13 2009-03-19 Santen Pharmaceutical Co., Ltd. 新規１，３，３－トリメチル－７－フェニル－３，４－ジヒドロ－１ｈ－キノキサリン－２－オン誘導体
WO2009035067A1 (ja) * 2007-09-13 2009-03-19 Santen Pharmaceutical Co., Ltd. １，３，３－トリメチル－７－フェニル－３，４－ジヒドロ－１ｈ－キノキサリン－２－オン誘導体からなるグルココルチコイド受容体アゴニスト
CN101400659A (zh) * 2006-03-14 2009-04-01 参天制药株式会社 具有糖皮质激素受体结合活性的新型1，2，3，4-四氢喹喔啉衍生物
CN101679317A (zh) * 2007-05-29 2010-03-24 参天制药株式会社 具有糖皮质激素受体结合活性且具有导入了磺酸酯或磺酰胺结构的苯基作为取代基的新型1，2，3，4－四氢喹喔啉衍生物
CN102149690A (zh) * 2008-09-12 2011-08-10 参天制药株式会社 含有具有导入了磺酸酯结构的苯基作为取代基的新型1，2，3，4-四氢喹喔啉衍生物的糖皮质激素受体激动剂

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60113032T2 (de) 2000-10-30 2006-07-06 Pfizer Products Inc., Groton Glukokortikoidrezeptor-Modulatoren
JP5054996B2 (ja) 2006-03-14 2012-10-24 参天製薬株式会社 グルココルチコイド受容体結合活性を有する新規１，２，３，４−テトラヒドロキノキサリン誘導体
KR20110010634A (ko) 2008-05-12 2011-02-01 산텐 세이야꾸 가부시키가이샤 치환 옥시기를 가지는 2,2,4-트리메틸-6-페닐-1,2-디하이드로퀴놀린 유도체를 포함하는 글루코코르티코이드 수용체 작용제
CN107922356A (zh) * 2015-08-25 2018-04-17 参天制药株式会社 [4‑(1,3,3‑三甲基‑2‑氧代‑3,4‑二氢‑1h‑喹喔啉‑7‑基)苯氧基]乙基氧基化合物或其盐

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101400659A (zh) * 2006-03-14 2009-04-01 参天制药株式会社 具有糖皮质激素受体结合活性的新型1，2，3，4-四氢喹喔啉衍生物
CN101679317A (zh) * 2007-05-29 2010-03-24 参天制药株式会社 具有糖皮质激素受体结合活性且具有导入了磺酸酯或磺酰胺结构的苯基作为取代基的新型1，2，3，4－四氢喹喔啉衍生物
WO2009035068A1 (ja) * 2007-09-13 2009-03-19 Santen Pharmaceutical Co., Ltd. 新規１，３，３－トリメチル－７－フェニル－３，４－ジヒドロ－１ｈ－キノキサリン－２－オン誘導体
WO2009035067A1 (ja) * 2007-09-13 2009-03-19 Santen Pharmaceutical Co., Ltd. １，３，３－トリメチル－７－フェニル－３，４－ジヒドロ－１ｈ－キノキサリン－２－オン誘導体からなるグルココルチコイド受容体アゴニスト
CN102149690A (zh) * 2008-09-12 2011-08-10 参天制药株式会社 含有具有导入了磺酸酯结构的苯基作为取代基的新型1，2，3，4-四氢喹喔啉衍生物的糖皮质激素受体激动剂

Also Published As

Publication number Publication date
US20190106393A1 (en) 2019-04-11
KR20180043329A (ko) 2018-04-27
JP2017043614A (ja) 2017-03-02
US10435379B2 (en) 2019-10-08
WO2017034006A1 (ja) 2017-03-02
JP2021138728A (ja) 2021-09-16
US20180244633A1 (en) 2018-08-30
HK1252159A1 (zh) 2019-05-17
JP7037687B2 (ja) 2022-03-16
US20190359577A1 (en) 2019-11-28
EA201890570A1 (ru) 2018-08-31
US10189796B2 (en) 2019-01-29
EP3342768A4 (en) 2019-01-23
CA2996278A1 (en) 2017-03-02
EP3342768A1 (en) 2018-07-04

Similar Documents

Publication Publication Date Title
CN107922356A (zh) [4‑(1,3,3‑三甲基‑2‑氧代‑3,4‑二氢‑1h‑喹喔啉‑7‑基)苯氧基]乙基氧基化合物或其盐
CN102713618B (zh) 蛋白激酶复合物和抑制剂
CN105307655B (zh) 哒嗪酮化合物及其用于制备治疗囊肿状纤维化的药物的应用
WO2014033449A1 (en) Kinase inhibitors
AU2002314330A1 (en) Amino nicotinate derivatives as glucokinase (GLK) modulators
EP1404335A1 (en) Amino nicotinate derivatives as glucokinase (glk) modulators
AU2014246870A1 (en) Urea derivatives useful as kinase inhibitors
WO2014162121A1 (en) Kinase inhibitors based upon n-alkyl pyrazoles
CN102089283B (zh) 含有具有取代氧基的2，2，4-三甲基-6-苯基-1，2-二氢喹啉衍生物的糖皮质激素受体激动剂
CN103703002B (zh) 具有parp抑制活性的新型化合物
JP2009084274A (ja) 新規１，３，３−トリメチル−７−フェニル−３，４−ジヒドロ−１ｈ−キノキサリン−２−オン誘導体
US8664221B2 (en) Method for treating an inflammatory disease by administering a 1,2,3,4- tetrahydroquinoxaline compound containing a phenyl group having a sulfonic acid ester structure introduced therein as a substituent
RU2503661C2 (ru) Новое производное индола, содержащее карбамоильную группу, уреидную группу и замещенную оксигруппу
HK1249102A1 (en) [4-(1, 3, 3-trimethyl-2-oxo-3, 4-dihydro-1h-quinoxalin-7-yl) phenoxy]ethyloxy compound or salt thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1252159

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20180417

WD01 Invention patent application deemed withdrawn after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1252159

Country of ref document: HK